Cargando…
The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a larg...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508233/ https://www.ncbi.nlm.nih.gov/pubmed/34638565 http://dx.doi.org/10.3390/ijms221910225 |
_version_ | 1784582047412518912 |
---|---|
author | Yuen, Man Lee Zhuang, Ling Rath, Emma M. Yu, Takun Johnson, Ben Sarun, Kadir Harun Wang, Yiwei Kao, Steven Linton, Anthony Clarke, Candice Julie McCaughan, Brian C. Takahashi, Ken Lee, Kenneth Cheng, Yuen Yee |
author_facet | Yuen, Man Lee Zhuang, Ling Rath, Emma M. Yu, Takun Johnson, Ben Sarun, Kadir Harun Wang, Yiwei Kao, Steven Linton, Anthony Clarke, Candice Julie McCaughan, Brian C. Takahashi, Ken Lee, Kenneth Cheng, Yuen Yee |
author_sort | Yuen, Man Lee |
collection | PubMed |
description | Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a large collection of MPM cell lines and MPM tissue samples to study the role of E-cadherin (CDH1) and microRNA on the efficacy of FAK inhibitors in MPM. The immunohistochemistry (IHC) results showed that the majority of MPM FFPE samples exhibited either the absence of, or very low, E-cadherin protein expression in MPM tissue. We showed that MPM cells with high CDH1 mRNA levels exhibited resistance to the FAK inhibitor PND-1186. In summary, MPM cells that did not express CDH1 mRNA were sensitive to PND-1186, and MPM cells that retained CDH1 mRNA were resistant. A cell cycle analysis showed that PND-1186 induced cell cycle disruption by inducing the G2/M arrest of MPM cells. A protein−protein interaction study showed that EGFR is linked to the FAK pathway, and a target scan of the microRNAs revealed that microRNAs (miR-17, miR221, miR-222, miR137, and miR148) interact with EGFR 3′UTR. Transfection of MPM cells with these microRNAs sensitised the CHD1-expressing FAK-inhibitor-resistant MPM cells to the FAK inhibitor. |
format | Online Article Text |
id | pubmed-8508233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85082332021-10-13 The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) Yuen, Man Lee Zhuang, Ling Rath, Emma M. Yu, Takun Johnson, Ben Sarun, Kadir Harun Wang, Yiwei Kao, Steven Linton, Anthony Clarke, Candice Julie McCaughan, Brian C. Takahashi, Ken Lee, Kenneth Cheng, Yuen Yee Int J Mol Sci Article Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a large collection of MPM cell lines and MPM tissue samples to study the role of E-cadherin (CDH1) and microRNA on the efficacy of FAK inhibitors in MPM. The immunohistochemistry (IHC) results showed that the majority of MPM FFPE samples exhibited either the absence of, or very low, E-cadherin protein expression in MPM tissue. We showed that MPM cells with high CDH1 mRNA levels exhibited resistance to the FAK inhibitor PND-1186. In summary, MPM cells that did not express CDH1 mRNA were sensitive to PND-1186, and MPM cells that retained CDH1 mRNA were resistant. A cell cycle analysis showed that PND-1186 induced cell cycle disruption by inducing the G2/M arrest of MPM cells. A protein−protein interaction study showed that EGFR is linked to the FAK pathway, and a target scan of the microRNAs revealed that microRNAs (miR-17, miR221, miR-222, miR137, and miR148) interact with EGFR 3′UTR. Transfection of MPM cells with these microRNAs sensitised the CHD1-expressing FAK-inhibitor-resistant MPM cells to the FAK inhibitor. MDPI 2021-09-23 /pmc/articles/PMC8508233/ /pubmed/34638565 http://dx.doi.org/10.3390/ijms221910225 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yuen, Man Lee Zhuang, Ling Rath, Emma M. Yu, Takun Johnson, Ben Sarun, Kadir Harun Wang, Yiwei Kao, Steven Linton, Anthony Clarke, Candice Julie McCaughan, Brian C. Takahashi, Ken Lee, Kenneth Cheng, Yuen Yee The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title | The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title_full | The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title_fullStr | The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title_full_unstemmed | The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title_short | The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM) |
title_sort | role of e-cadherin and microrna on fak inhibitor response in malignant pleural mesothelioma (mpm) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508233/ https://www.ncbi.nlm.nih.gov/pubmed/34638565 http://dx.doi.org/10.3390/ijms221910225 |
work_keys_str_mv | AT yuenmanlee theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT zhuangling theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT rathemmam theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT yutakun theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT johnsonben theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT sarunkadirharun theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT wangyiwei theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT kaosteven theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT lintonanthony theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT clarkecandicejulie theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT mccaughanbrianc theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT takahashiken theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT leekenneth theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT chengyuenyee theroleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT yuenmanlee roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT zhuangling roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT rathemmam roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT yutakun roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT johnsonben roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT sarunkadirharun roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT wangyiwei roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT kaosteven roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT lintonanthony roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT clarkecandicejulie roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT mccaughanbrianc roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT takahashiken roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT leekenneth roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm AT chengyuenyee roleofecadherinandmicrornaonfakinhibitorresponseinmalignantpleuralmesotheliomampm |